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Background:  Plasma  aldosterone  concentration  (PAC)  is related  to cardiac  remodeling  in patients  with
hypertension.  However,  we do not  know  the detailed  relationship  between  changes  in PAC and  regression
of  left  atrial  (LA)  volume  following  long-term  treatment  with  angiotensin  II receptor  blocker  (ARB)  or
calcium-channel  blocker  (CCB).
Objective:  The  aim of  this  study  was  to  investigate  the  effects  of anti-hypertensive  monotherapy,  an ARB
irbesartan  or  a CCB  amlodipine,  on  PAC  and  LA  reverse  remodeling  in  hypertensive  patients.
Methods:  A  total  of 48  patients  with  untreated  hypertension  were  randomly  assigned  to  irbesartan  (ARB
group,  n  = 26)  and  amlodipine  (CCB  group,  n  =  22).  We  examined  the  correlation  between  LA  volume index
(LAVI) and  other  echocardiographic  parameters  or PAC  (n = 40)  at the  baseline  and  after  12 months  of
treatment.
Results:  After  12  months,  blood  pressure  (BP)  decreased  similarly  in  both  groups.  LAVI  and  PAC signiﬁ-
cantly  decreased  in  the  ARB  group,  but not  in  the  CCB  group  (−16 ±  8%  vs.  22  ±  9%,  p <  0.01,  −16  ±  9%  vs.
11  ± 9%,  p < 0.05).  Larger  %-decrease  in  PAC  was  associated  with  larger  %-reduction  of  LAVI  in the ARB
group  (r  =  0.54,  p < 0.05),  but  not  in  the CCB  group.
Conclusions:  While  BP  reduction  was  similar  between  the  two  groups,  decrease  in LA volume  was  larger
in the  ARB  group  than  in  the  CCB  group.  Decrease  in  LA  volume  was  larger in patients  with  a  greater
decrease in  PAC  than  in  those  with  smaller  decrease  in PAC.  ARB may  facilitate  reverse  remodeling  of LA
 in  hy
3  Japthrough  decreases  in  PAC
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Hypertension leads to adverse cardiac remodeling, such as left
trial (LA) enlargement, left ventricular (LV) hypertrophy, and car-
iac ﬁbrosis [1,2]. Cardiac remodeling is associated with increased
orbidity and mortality due to subsequent heart failure [3]. Clin-
cal studies have shown that inhibiting the renin–aldosterone
ystem using angiotensin-converting enzyme (ACE) inhibitors or
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edicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya 663-8501,
apan. Tel.: +81 798 45 6553; fax: +81 798 45 6551.
E-mail address: masuyama@hyo-med.ac.jp (T. Masuyama).
914-5087/$ – see front matter © 2013 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2013.08.004pertensive  patients.
anese  College  of Cardiology.  Published  by Elsevier  Ltd.  All  rights  reserved.
angiotensin type II receptor blockers (ARB) induced cardiac reverse
remodeling [4–6]. Moreover, plasma aldosterone has a crucial
role in development of cardiac remodeling [7]. We  previously
reported that the inhibition of plasma aldosterone works as a
contributor to regression of LV mass in hypertensive patients fol-
lowing long-term treatment with ARB or calcium channel blocker
(CCB) [8].
LA enlargement [9–13] is strongly correlated with atrial ﬁbril-
lation and mortality in hypertensive patients. Further, LA reverse
remodeling by the ARB losartan was  reported to be associated with
absence of new onset of atrial ﬁbrillation [5]. However, it is unclear
whether ARB or CCB could decrease plasma aldosterone concentra-
tion (PAC) and LA volume in patients with untreated hypertension.
Thus, the aim of this study was to investigate the impact of decrease
vier Ltd. All rights reserved.
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in the ARB group, but not in the CCB group. The E and A were sig-
niﬁcantly increased in the CCB group, but not in the ARB group
(Table 2).
Table 1
Baseline characteristics of study subjects.
ARB (n = 26) CCB (n = 22) p-Value
Age (years) 63 ± 12 60 ± 13 0.68
Sex  (female/male) 7F, 19M 6F, 16M 0.32
BMI  24 ± 3 24 ± 4 0.17
SBP  (mmHg) 161 ± 20 162 ± 19 0.29
DBP  (mmHg) 92 ± 15 94 ± 12 0.60
HR  (bpm) 69 ± 12 66 ± 17 0.52
LAD  (mm) 36 ± 6 36 ± 5 0.92
LAVI (ml/m2) 24 ± 7 22 ± 6 0.26
LVEDD (mm)  48 ± 5 49 ± 4 0.60
LVESD (mm)  30 ± 5 29 ± 7 0.47
RWT  0.40 ± 0.06 0.41 ± 0.01 0.51
LVEF (%) 67 ± 7 67 ± 5 0.45
LVMI (g/m2) 96 ± 26 102 ± 16 0.45
Comorbidity
Dyslipidemia (%) 8 (31) 10 (45) 0.29
Smoking (%) 2 (7) 1 (5) 0.65
Baseline medication
Statin n (%) 4 (15) 7 (32) 0.9406 M.  Masaki et al. / Journal o
n PAC as a contributor to regression of LA volume index in hyper-
ensive patients following long-term treatment with ARB or CCB.
aterials and methods
ubjects
We  enrolled 48 patients with untreated hypertension who
resented to the outpatient clinic of Hyogo College of Medicine
etween January 2010 and December 2012. Patients were included
n the study if they met  the following criteria: 20 years of age
r older, systolic blood pressure (SBP) and diastolic blood pres-
ure (DBP) of 140 and 90 mmHg  or over. Patients were excluded
f they had secondary hypertension of any cause, angina pectoris
r acute coronary artery disease, current or recent history of con-
estive heart failure, valvular heart diseases, cardiac arrhythmias,
enal dysfunction (serum creatinine level over 2.0 mg/dl), or dia-
etes mellitus. Informed consent was obtained from all patients,
nd the study was designed to comply with the ethical principles
f our institution. Eligible patients were randomly assigned in a 1:1
atio to receive either amlodipine 2.5 mg  daily (CCB group) or irbe-
artan 100 mg  daily (ARB group). Target SBP and DBP were below
40 and 90 mmHg, respectively. If blood pressure reduction did
ot achieve the target level after 4 weeks, the dose of amlodip-
ne was doubled to 5 mg,  and irbesartan to 200 mg.  The third and
ourth steps of treatment included the addition of a thiazide and/or
lpha-blocker.
lood chemistry
Among 48 subjects, we could collect blood samples for PAC and
-type natriuretic peptide (BNP) measurement from 20 patients
ach in the ARB and CCB groups. Blood samples (n = 40) were taken
etween 09.00 and 11.00 h and were immediately placed on ice and
entrifuged within 1 h. The specimens were stored at −80 ◦C until
nalysis. PAC was  measured with a radioimmunoassay kit (SPAC-
 Aldosterone Kit; Otsuka Pharmaceutical Co., Ltd., TFB, Tokyo,
apan). Plasma BNP concentration was measured with a Shionoria
NP kit (Shionogi Inc., Tokyo, Japan).
chocardiographic studies
Transthoracic echocardiography was performed at baseline and
2 months after treatment in all patients. Echocardiography was
ecorded with iE33 (Philips Medical Systems, Bothell, WA,  USA). A
tandard, comprehensive, M-mode, 2-dimensional echocardiogra-
hy and Doppler study were conducted according to the guideline
f the American Society of Echocardiography [14]. LA volume was
alculated with a formula using an ellipsoid model and was indexed
o the body surface area, i.e. LAVI [15]. LV mass index (LVMI)
nd relative wall thickness (RWT) were measured by the method
escribed previously [8]. Peak velocities of early diastolic phase
E) and late diastolic phase (A) of mitral inﬂow, and the E/A ratio
ere measured by pulsed-wave Doppler echocardiography with
he sample volume between mitral leaﬂet tips. Mitral annulus
elocities (E′) and E/E′ ratio were measured at the septal annulus
y tissue Doppler imaging.
thics
This study was conducted in accordance with the prin-
iples outlined in the Declaration of Helsinki after receiving
pproval from the institutional review board of Hyogo College of
edicine. All subjects provided written informed consent prior to
articipation.iology 63 (2014) 205–210
Statistical analysis
The primary outcomes included changes in PAC and LA vol-
ume  in hypertensive patients following long-term treatment with
amlodipine or irbesartan. Continuous data are presented as mean
(±SD). We  compared values at baseline and after treatment using
paired t-test. The correlations between LAVI and PAC, LVMI and
E/E′ were examined using linear regression analysis. A p-value less
than 0.05 was considered signiﬁcant. Statistical computations were
performed with JMP  version 10.0.1 (SAS Institute, Inc., Cary, NC,
USA).
Results
Patient characteristics
There were 35 men  and 13 women with a mean age of 62 years.
The ﬁnal dose of amlodipine was 145 ± 57 mg/day and that of irbe-
sartan was 4.4 ± 1.2 mg/day. Thiazide indapamide 1 mg  was added
to the basal medications in two patients in the ARB group and three
patients in the CCB group and the alpha blocker doxazosin 1 mg
was added to three patients in the CCB group and no patients in the
ARB group. Baseline characteristics were similar in both groups of
patients (Table 1).
Changes in blood pressure and echocardiographic parameters and
humoral factors
After 12 months of treatment, SBP, DBP, and LVMI decreased
similarly in both ARB and CCB groups. Heart rate (HR), E/A, deceler-
ation time (DT) of E wave and natural logarithm of brain natriuretic
peptide (Ln BNP) did not change in either group. The LA dimension
(LAD) tended to decrease in the ARB group, and tended to increase
in the CCB group. The LAVI, E/E′, and PAC signiﬁcantly decreasedARB, angiotensin II receptor blocker; CCB, calcium channel blocker; BMI, body mass
index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate;
LAD, left atrial diameter; LAVI, left atrial volume index; LVEDD, left ventricular end-
diastolic diameter; LVESD, left ventricular end-systolic diameter; RWT, relative wall
thickness; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index.
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Table  2
Changes in hemodynamic and echocardiographic parameters, and hormone levels in ARB and CCB groups.
ARB (n = 26) CCB (n = 22)
Before treatment 12 months Before treatment 12 months
Age (years) 63 ± 12 60 ± 13
Sex  (female/male) 7F, 19M 6F, 16M
BMI  24 ± 3 24 ± 3 24 ± 4 24 ± 4
SBP  (mmHg) 161 ± 20 129 ± 16** 162 ± 19 132 ± 14**
DBP (mmHg) 92 ± 15 77 ± 14** 94 ± 12 81 ± 10**
HR (bpm) 69 ± 12 69 ± 13 66 ± 17 73 ± 11
PAC  (pg/dl) 126 ± 64 101 ± 59* 124 ± 51 134 ± 69
Ln  BNP (pg/ml) 3.0 ± 1.1 2.8 ± 0.9 2.8 ± 1.0 2.6 ± 1.0
LAD  (mm)  36 ± 6 35 ± 5 36 ± 5 37 ± 4
LAVI  (ml/m2) 24 ± 7 20 ± 6** 22 ± 6 24 ± 6
LVEDD  (mm) 48 ± 5 47 ± 4** 48 ± 4 49 ± 4
LVESD  (mm)  30 ± 5 29 ± 4 29 ± 7 30 ± 4
RWT  0.40 ± 0.06 0.37 ± 0.04* 0.41 ± 0.01 0.38 ± 0.05*
LVEF (%) 67 ± 7 67 ± 5 67 ± 5 67 ± 6
LVMI  (g/m2) 96 ± 26 78 ± 12** 102 ± 16 91 ± 15**
E (m/s) 63 ± 11 58 ± 14 56 ± 13 68 ± 15**
A (m/s) 77 ± 17 73 ± 16 70 ± 19 79 ± 20**
E/A 0.80 ± 0.14 0.81 ± 0.21 0.85 ± 0.31 0.91 ± 0.27
DT  (ms) 215 ± 52 195 ± 39 205 ± 46 203 ± 53
E′ (cm/s) 5.6 ± 1.5 6.6 ± 1.7*** 5.7 ± 1.6 6.0 ± 1.7
E/E′ 11 ± 5 9 ± 3* 11 ± 3 12 ± 3
ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; PAC,
plasma  aldosterone concentration; Ln BNP, natural logarithm brain natriuretic peptide; LAD, left atrial diameter; LAVI, left atrial volume index; LVEDD, left ventricular end-
diastolic diameter; LVESD, left ventricular end-systolic diameter; RWT, relative wall thickness; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; DT,
deceleration time.
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a* p < 0.05 vs. baseline.
** p < 0.01 vs. baseline.
*** p < 0.001 vs. baseline.
ffects of ARB and CCB on LAVI, LVMI, and PAC
Percent changes from the baseline in LAVI, LVMI, and PAC were
igniﬁcantly different between the ARB and CCB groups (−16 ± 8%
s. 22 ± 9%, p < 0.01, −9 ± 2% vs. −16 ± 2%, p < 0.05, −16 ± 9% vs.
1 ± 9%, p < 0.05, respectively) (Figs. 1–3).
orrelations between LAVI and PAC, and LVMI and E/E′
Percent change in PAC was correlated with percent change in
AVI in the ARB group (r = 0.54, p < 0.05), but not in the CCB group
Fig. 4). Percent change in LVMI was correlated with that in LAVI
n the ARB group (r = 0.46, p < 0.05), but not in the CCB group
Fig. 5). Percent change in E/E′ was correlated with that in LAVI
n the ARB group (r = 0.53, p < 0.01) and in the CCB group as well
ig. 1. Percent changes in left atrial volume index (LAVI). LAVI decreased in the
RB group but not in the CCB group after 12 months of treatment. p < 0.05. ARB,
ngiotensin II receptor blocker; CCB, calcium channel blocker.(r = 0.48, p < 0.05, Fig. 6). Percent change in SBP was not correlated
with percent change in LAVI either in the ARB group or the CCB
group.
Discussion
The main ﬁndings in the present study were: (1) while blood
pressure reduction over 12 months was similar between the ARB
and CCB groups, PAC, E/E′, and LAVI decreased only in the ARB
group; and (2) in the ARB group, percent decrease in LAVI was
correlated with percent decrease in PAC.These data suggest that ARB decreased LV ﬁlling pressure and
LA volume through reduction of PAC in hypertensive patients.
Fig. 2. Percent changes in left ventricular mass index (LVMI). Percent decrease
in  LVMI was greater in the ARB group than that in the CCB group. p < 0.05. ARB,
angiotensin II receptor blocker; CCB, calcium channel blocker.
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Fig. 3. Percent change in plasma aldosterone concentration (PAC). PAC decreased
in  the ARB group but not in the CCB group after 12 months of treatment. ARB,
angiotensin II receptor blocker; CCB, calcium channel blocker.
Fig. 4. Correlation between percent change in left atrial volume index (LAVI) and
percent change in plasma aldosterone concentration (PAC). Larger percent decrease
in  PAC was associated with larger percent reduction in LAVI in the ARB group but
n
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Fig. 6. Correlation between percent change in left atrial volume index (LAVI) and
percent change in ratio of transmitral E wave peak velocity to average mitral annular
E′ velocity (E/E′). Larger percent decrease in E/E′ was associated with larger percent
reduction of LAVI in ARB group. Larger percent increase in E/E′ was  associated with
larger percent increase in LAVI in the CCB group. Open circles stand for the data of
the  ARB group, and closed circles are those of the CCB group. ARB, angiotensin IIot  in the CCB group. Open circles stand for the data of the ARB group, and closed
ircles are those of the CCB group. ARB, angiotensin II receptor blocker; CCB, calcium
hannel blocker.
ffect of irbesartan on hemodynamics, left ventricular mass, and
eft atrial volumeIn our study, the reduction in systolic and diastolic blood pres-
ure after 12-month treatment was not signiﬁcantly different
etween the ARB and CCB groups. Body weight and heart rate
id not change throughout the study period. Nonetheless, LV mass
ig. 5. Correlation between percent change in left atrial volume index (LAVI) and
ercent change in left ventricular mass index (LVMI). Larger percent decrease in
VMI was  associated with larger percent reduction in LAVI in the ARB group than
n  the CCB group. Open circles stand for the data for the ARB group, and closed
ircles are those for the CCB group. ARB, angiotensin II receptor blocker; CCB, calcium
hannel blocker.receptor blocker; CCB, calcium channel blocker.
decreased more in the ARB group than in the CCB group (−9 ± 2%
vs. −16 ± 2%, p < 0.05, Fig. 2). LAD and LAVI decreased only in the
ARB group, not in the CCB group (Table 2 and Fig. 1). In other words,
the magnitude of decrease not only in LA volume, but also in E/E′
and LVMI was larger in the ARB group than in the CCB group. These
data suggest that the ARB irbesartan may  have a beneﬁcial effect
on LV ﬁlling pressure and LA volume as well.
Role of left atrial structural remodeling for cardiac events
Enlargement of LA has adverse cardiovascular outcomes, includ-
ing stroke [9], heart failure [16–18], atrial ﬁbrillation [19], and
mortality [20]. LA enlargement has been strongly associated with
LV diastolic dysfunction, independent of LV ejection fraction, age,
gender, and cardiovascular risk score [21,22]. Since LA enlargement
can be attributed to a sustained elevation of LV ﬁlling pressure
and an atrial volume overload due to diastolic dysfunction in
hypertensive patients [23,24], the LA volume reduction might be
associated with improvement in cardiovascular events. However,
it has not been fully clariﬁed whether the LA volume reduction
directly results in the improvement in cardiovascular outcomes.
Effect of irbesartan on PAC and LA reverse remodeling
In the ARB group of the present study, the larger decrease in
PAC was  associated with the larger reduction of LAVI. Elevated
plasma aldosterone levels promote hypertension, cardiac ﬁbrosis,
left ventricular hypertrophy, and endothelial dysfunction [8,25].
Conversely, blockade of the renin–angiotensin–aldosterone sys-
tem can result in favorable effects on cardiac remodeling. In the
LIFE trial, the ARB losartan reduced LA diameter index in hyperten-
sive patients with LV hypertrophy. In the SILVHIA study, irbesartan
improved myocardial ﬁbrosis and diastolic dysfunction in patients
with hypertension with LV hypertrophy [26,27]. Moreover, irbe-
sartan has an anti-inﬂammatory effect and an anti-oxidative effect,
in addition to its antihypertensive effect [28–30]. Inhibition of the
renin–angiotensin–aldosterone system by ARB or ACE inhibitors
was reported to improve LA ﬁbrotic change, which is found in atrial
tissue of hypertensive patients [31,32]. Further, no correlation was
seen between percent change in SBP and percent change in LAVI
either in the ARB group or in the CCB group. Thus, LA reverse remod-
eling may  be attributed to the reduction in LA afterload and/or
to the decrease in PAC due to ARB, which in turn would improve
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iastolic dysfunction through reduction of LVMI and LV ﬁlling pres-
ure.
ffect of amlodipine on PAC and LA volume
The L-type CCB, amlodipine, might activate the
enin–angiotensin–aldosterone system by an increase in sym-
athetic tone via a rapid and large reduction in blood pressure
33–35]. Nishimura et al. described increment in LV end-diastolic
ressure as well as prolongation of the time constant of relaxation
y CCB [36]. Chen et al. showed that hypertensive patients on CCB
herapy seemed to have larger size of LAVI compared with patients
n ACE inhibitors or ARBs [37]. Amlodipine has been reported
o increase the prevalence of congestive heart failure more than
rbesartan [38].
In our study, LA volume was not changed by amlodipine treat-
ent, with an effective percent change of 22% over 12 months.
oreover, there was no difference in E/E′ and PAC between the
aseline and follow-up in the CCB group, in which a sustained high
evel of PAC may  lead to elevation of LV ﬁlling pressure and LA
ressure. Amlodipine may  not supress LA remodeling because of
esser magnitude of LVMI reduction or sustained high level of PAC.
wo patients in the CCB group showed over 150% increase in LAVI.
lthough both patients had modest increase in body mass index
rom 24 to 25 kg/m2, their homeostasis model assessment ratio
HOMA-R) markedly rose from 3.4 to 8.4 and 1.2 to 4.5 during the
tudy period. Development in insulin resistance might be associ-
ted with LAVI increase. We  need more patients to conﬁrm the
xact mechanisms of increment in LAVI.
The present study showed that more reduction in PAC was pro-
ided with irbesartan than with amlodipine, and this might reduce
V hypertrophy, LA volume, and LV ﬁlling pressure. LA size reduc-
ion by the ARBs, losartan or valsartan was associated with absence
f new onset of atrial ﬁbrillation in patients with hypertension
5,39–41]. Irbesartan decreased LV ﬁlling pressure and LV hyper-
rophy much more than amlodipine despite similar blood pressure
owering, which might reduce the risk of future atrial ﬁbrillation in
atients with hypertension.
imitations
Several limitations are included in this study. First, this is a
ingle-center study conducted only in Japan and the number of
nrolled patients is limited. Therefore, a large multicenter study
s needed to conﬁrm our results. Second, we used only one drug
or each patient group (irbesartan and amlodipine). Although they
re common medications for treatment of hypertension in our
nstitute, comparison with other ARBs and CCBs may  be needed
n the future. Third, neither hemodynamic data (such as LV or
trial pressure) nor myocardial biopsy for estimation of ﬁbrosis
as available in the present study. In future, we  need to elaborate
he detailed relations between cardiac hemodynamics, myocardial
issue pathology, and left atrial structure.
Fourth, we only measured a single point of daytime BP, and noc-
urnal BP might be different in the ARB and CCB groups. Therefore
4-h ambulatory BP monitoring may  be necessary in future studies.
onclusions
The ARB irbesartan seems to decrease PAC, LVMI, and LAVI,
ifferently from the CCB amlodipine. There were signiﬁcant cor-
elations between percent decrease in PAC and percent decreases
n LVMI and LAVI. These data suggest that suppression of PAC by
rbesartan contributed to reverse remodeling of LA and LV in hyper-
ensive patients.
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